Solian

Solian is the brand name for amisulpride, a selective dopamine D2 and D3 receptor antagonist used as an antipsychotic. It belongs to the benzamide class of antipsychotics. At low doses, amisulpride preferentially blocks limbic D2/D3 receptors, producing antipsychotic effects with a relatively low risk of extrapyramidal symptoms; at higher doses, the profile resembles a more typical antipsychotic.

It is approved for the treatment of schizophrenia in adults in many regions and has been used for acute psychosis. In some markets, low-dose amisulpride has been explored for mood disorders with psychotic features or dysthymia, though indications vary by country. It is typically taken by mouth once or twice daily.

Pharmacokinetics: amisulpride is absorbed orally with peak plasma concentrations occurring within a few hours; its elimination half-life is around 12 to 20 hours, and most of the drug is excreted unchanged in the urine with limited hepatic metabolism.

Adverse effects may include extrapyramidal symptoms and hyperprolactinemia, particularly at higher doses; weight change and sedation can occur. As with other antipsychotics, caution is advised in patients with kidney impairment, and hypersensitivity to the drug is a contraindication. The regulatory status of Solian varies by country, and in some places it is available as a generic amisulpride.